Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control · 2016
[Efficacy of repeated application of praziquantel in treatment of hepatic fibrosis due to schistosomiasis].
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hong-Bao Liao, Ming Shen
Аннотация
OBJECTIVE: To evaluate the efficacy of repeated application of praziquantel in the treatment of hepatic fibrosis due to schistosomiasis.
METHODS: A total of 60 patients with schistosomiasis hepatic fibrosis (clinically diagnosed cases) were selected and divide into a treatment group and control group randomly, with 30 cases each group. The patients in the treatment group were given praziquantel［30 mg/ (kg·d) for 2 days］each year for three consecutive years, on the basis of the conventional liver protection therapy and symptomatic treatment. The patients in the control group were given the conventional liver protection therapy and symptomatic treatment. All the treatment duration was 36 months. The clinical symptoms were observed, and the liver function, and the levels of HA, LN, IV-C, and PCIII were detected in the two groups before and after the treatment.
RESULTS: The clinical symptoms and liver function improved, and the HA, LN, IV-C, PCIII levels were decreased in the treatment group with varying degrees, and the total effective rate was 93% (26/28). The total effective rate in the control group was 60% (16/27). There was a significant difference between the two groups in the total effective rate (P < 0.05).
CONCLUSIONS: The repeated application of praziquantel has a better therapeutic efficacy in the treatment of hepatic fibrosis due to schistosomiasis.
METHODS: A total of 60 patients with schistosomiasis hepatic fibrosis (clinically diagnosed cases) were selected and divide into a treatment group and control group randomly, with 30 cases each group. The patients in the treatment group were given praziquantel［30 mg/ (kg·d) for 2 days］each year for three consecutive years, on the basis of the conventional liver protection therapy and symptomatic treatment. The patients in the control group were given the conventional liver protection therapy and symptomatic treatment. All the treatment duration was 36 months. The clinical symptoms were observed, and the liver function, and the levels of HA, LN, IV-C, and PCIII were detected in the two groups before and after the treatment.
RESULTS: The clinical symptoms and liver function improved, and the HA, LN, IV-C, PCIII levels were decreased in the treatment group with varying degrees, and the total effective rate was 93% (26/28). The total effective rate in the control group was 60% (16/27). There was a significant difference between the two groups in the total effective rate (P < 0.05).
CONCLUSIONS: The repeated application of praziquantel has a better therapeutic efficacy in the treatment of hepatic fibrosis due to schistosomiasis.